Background: Hepatocellular carcinoma is highly refractory to most chemotherapeutic agents. Clofazimine, a riminophenazine compound used to treat leprosy since 1962, inhibits various cancer cell lines, including hepatocellular carcinoma cell lines, via phospholipase A 2 dependant processes. Clofazimine also inhibits/>770-glycoprotein, the mdrl gene product.
Introduction
Hepatocellular carcinoma is prevalent in sub-Saharan Africa and eastern Asia [1] , and is frequently related to chronic Hepatitis B or C virus infection, as well as to chronic aflatoxin exposure [2] . Patients who acquire the hepatitis B virus at birth, or during early childhood are at the greatest risk of developing hepatocellular carcinoma [2] . The treatment of choice is surgery, although radical resection is feasible in only a very small percentage of patients. Unresectable hepatocellular carcinoma has a very poor prognosis with a median survival of about 6-8 weeks being reported [3] .
The disease is highly chemotherapy-refractory, possibly related to over-expression of the mdrl gene [4, 5] . A number of chemotherapeutic agents including doxorubicin, 5-fluorouracil, etoposide, cisplatin and raltitrexed, as well as interferon-a and tamoxifen, have been shown to have limited efficacy [5, 6] .
Clofazimine(B663;3-(p-chloroanilino-10-(p-chlorophenyll)-2,10-dihydro-2-isopropyliminophenazine), a riminophenazine compound, has been used in the treatment of leprosy since 1962, usually in combination with dapsone or rifampicin, and is the drug of choice in controlling erythema nodosum leprosum [7] . Recent studies have shown that clofazimine as well as a derivative, B669, are potent inhibitors of various cancer cell lines including FaDu; a human squamous carcinoma cell line, HeLa; a human cervix carcinoma cell line, T24; a human transitional carcinoma cell line and PLC; a hepatocellular carcinoma cell line which has intrinsic multidrug resistance [8] . The primary molecular target of riminophenazines is Na + , K + -ATPase, a membraneassociated enzyme essential for tumour cell proliferation [9] . Lysophosphatidylcholine, generated by riminophenazine-induced-stimulation of tumour cell phospholipase A 2 , appears to mediate this inhibitory effect [9] . Clofazimine also enhances neutrophil phagocytic and cytotoxic activity by increasing the generation of reactive oxidants [9] . Preliminary studies of oral clofazimine, at a dose of 30 mg/kg, delayed the development of carcinogen-induced squamous carcinomas in mice, and mammary tumours in rats [10] . High levels of clofazimine were observed in tumour and liver tissue relative to other organs [10] . Minor side effects reported include hyperpigmentation of the skin and conjunctivae, skin rashes and gastrointestinal upset. We report a phase II study of the riminophenazine compound, clofazimine, in unresectable and metastatic hepatocellular carcinoma.
Patients and methods (Table 1)
Thirty patients (26 males and 4 females) with previously untreated, either unresectable or metastatic hepatocellular carcinoma, were included in this study. The diagnosis of hepatocellular carcinoma was made in patients with a liver mass demonstrated on ultrasound, CT scan or MRI scan, confirmed by either histology, cytology, or by an a-fetoprotein level of greater than 1000 kU/1. Seventeen patients had an ECOG Performance Status of one, and 13 patients an ECOG Performance Status of two. All patients were geographically accessible, and had signed an informed consent form. The study was approved by the Committee for Research on Human Subjects (Medical) of the University of the Witwatersrand. Twenty-five patients were of African origin, two of European origin, two of Indian origin and one of Chinese origin. Only three patients were negative for both the Hepatitis B and C viruses. Distant metastases were seen in five patients including three patients with soft tissue metastases, and two patients with pulmonary metastases. The remaining 25 patients had locally advanced, surgically unresectable liver tumours.
All patients received clofazimine 600 mg orally daily for two weeks, followed by 400 mg orally daily until disease progression or death. This dose schedule was based on pharmacokinetic data in patients with leprosy, and in healthy volunteers [11] [12] [13] . A loading dose was given to rapidly approach a steady state, due to the slow release of clofazimine from fatty and reticuloendothelial tissue [11, 12] .
Patients were evaluated every four weeks by clinical examination, hepatic scan, and serum a-feto-protein level. A complete response (CR) was defined as the disappearance of all known disease for at least four weeks, while a partial response (PR), was at least a 50% decrease in the sum of the products of the perpendicular diameters of the tumour measurements. In addition there must be no new lesions or progression of any other lesions. Stable disease (SD) was defined as a decrease of less than 50%, or an increase of less than 25%, in the size of the measurable lesions, while progressive disease (PD) was a 25% or more increase in the size of one or more of the measurable lesions, or the appearance of any new lesions. Survival and time to treatment failure were measured from the date of entry onto the study.
Results
There were three partial responses (10%, 95% CI: 2%-27%), one of a patient with a soft tissue metastasis, and two in patients with unresectable primary liver tumours. Patient one was a 58-year-old, hepatitis C virus positive, black male who presented with a 90 mm by 90 mm soft tissue mass on his back, a 77 mm by 77 mm liver mass, and an a-feto-protein of 22980 kU/1. After six months of clofazimine the soft tissue mass had disappeared, the liver mass had decreased in size by 90%, and the a-fetoprotein had dropped to 47 kU/1. The patient remained in a good partial remission for a further 12 months. After 18 months of clofazimine the disease significantly progressed, and the patient was taken off study. After an initial response to salvage therapy, he died 25 months after the start of the clofazimine.
Patient two was a 65-year-old, hepatitis B and C virus negative, black male, who presented following a failed partial hepatectomy. He had an a-feto-protein of 25770 kU/1, and 50 mm by 80 mm mass involving the left lobe of the liver. After six months of clofazimine the a-fetoprotein level had decreased to 12319 kU/1 and the liver mass had decreased to 40 mm by 20 mm. The patient remains stable in a good partial remission, after 12 months on clofazimine.
Patient three was a 55-year-old hepatitis B virus positive black male, who presented with a 100 mm by 60 mm inoperable mass involving both lobes of the liver, and an a-feto-protein of 16.5 kU/1. After 12 weeks of clofazimine the liver mass had decreased to 30 mm by 30 mm and the a-feto-protein level had decreased to 8.3 kU/1. He remained in a good partial remission for 12 months, before progressing and dying 18 months after starting clofazimine.
Early disease progression was seen in 14 patients (46.7%), while disease stabilization was achieved in 13 patients (43.3%), lasting between three and 20 months. A total of eight patients survived for six months or more, with six patients (20%) surviving for 12 months or more. The overall median time to treatment failure was 69 days (95% CI: 56-115 days), while the overall median survival was 91 days (95% CI: 78-167 days).
Mild adverse events included an eczematous skin rash in five patients, hyperpigmentation of sun-exposed areas in 13 patients, and palpitations in one patient. None of these were severe, requiring treatment, or the cessation of the clofazimine therapy.
Univariate analyses of pretreatment variables including initial age, sex, weight, performance status, serum bilirubin, serum LDH, serum albumin, presence or absence of ascites and encephalopathy, Child's stage, a-fetoprotein level, haemoglobin, glucose level and serum ferritin showed a raised serum LDH (P = 0.0003), an ECOG performance status of 2 (P = 0.0092), Child's stage B (P -0.0275) and a raised serum bilirubin (P = 0.0448) had a significant negative impact on overall survival. A logrank multivariate analysis however showed only a raised pretreatment LDH level (P = 0.0003), and a performance status of 2 (P = 0.0125), negatively influenced survival.
Discussion
Hepatocellular carcinoma is a common cancer throughout the world, especially in Asia and Africa, with up to a million cases being diagnosed each year [5] . Patients usually present with advanced unresectable disease, with a median survival of 6-8 weeks from diagnosis, as conventional chemotherapy is of limited value [5, 6] . Our results of an objective response rate of 10% (three patients), as well as 43.3% (13 patients) disease stabilization for up to 20 months, and an overall median survival of 13 weeks, represent a small improvement. As clofazimine is well tolerated, with minimal toxicity, this study suggests that oral clofazimine may prove to be useful in the treatment of hepatocellular carcinoma. Clofazimine, in addition to exhibiting direct cytotoxicity via phospholipase A 2 dependant processes, also inhibits /j/70-glycoprotein, the mdrl gene product [9, 10] . Further studies with clofazimine, as well as other active riminophenazine compounds, alone or in combination with agents such as doxorubicin, which have limited single agent activity in hepatocellular carcinoma [4, 5] , possibly due to the over-expression of the mdrl gene product, may prove to be of greater value in the therapy of this highly chemotherapy resistant malignancy. Indeed up to 80% of hepatocellular carcinomas express the/7770-glycoprotein at diagnosis [14] .
